Celeste Decker

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · Molecular Genetics and Metabolism · 2008 · 216 citations

Life Sciences, Biochemistry, Clinical Biochemistry +8

The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects

Paul Harmatz, Eugen Mengel, Roberto Giugliani et al. · Molecular Genetics and Metabolism · 2013 · 148 citations · Full text

Medicine, Physiology, Exercise Testing +15

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long‐term pulmonary function in patients treated with recombinant human <i>N</i>‐acetylgalactosamine 4‐sulfatase

Paul Harmatz, Zi‐Fan Yu, Roberto Giugliani et al. · Journal of Inherited Metabolic Disease · 2010 · 92 citations · Full text

Health Professions, Pharmacotherapy, Clinical Biochemistry +10

Enzyme replacement therapy for mucopolysaccharidosis VI: long‐term cardiac effects of galsulfase (Naglazyme^®) therapy

Elizabeth Braunlin, H. Rosenfeld, Christoph Kampmann et al. · Journal of Inherited Metabolic Disease · 2012 · 70 citations · Full text

Life Sciences, Biochemistry, Cardiology +10

Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

Celeste Decker, Zi‐Fan Yu, Roberto Giugliani et al. · Journal of Pediatric Rehabilitation Medicine · 2010 · 66 citations · Full text

Life Sciences, Pediatrics, Pharmacotherapy +14